These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
197 related articles for article (PubMed ID: 21433156)
1. 31P MRSI and 1H MRS at 7 T: initial results in human breast cancer. Klomp DW; van de Bank BL; Raaijmakers A; Korteweg MA; Possanzini C; Boer VO; van de Berg CA; van de Bosch MA; Luijten PR NMR Biomed; 2011 Dec; 24(10):1337-42. PubMed ID: 21433156 [TBL] [Abstract][Full Text] [Related]
2. 31P magnetic resonance spectroscopic imaging with polarisation transfer of phosphomono- and diesters at 3 T in the human brain: relation with age and spatial differences. Wijnen JP; Scheenen TW; Klomp DW; Heerschap A NMR Biomed; 2010 Oct; 23(8):968-76. PubMed ID: 20669234 [TBL] [Abstract][Full Text] [Related]
3. Investigation of breast cancer using two-dimensional MRS. Thomas MA; Lipnick S; Velan SS; Liu X; Banakar S; Binesh N; Ramadan S; Ambrosio A; Raylman RR; Sayre J; DeBruhl N; Bassett L NMR Biomed; 2009 Jan; 22(1):77-91. PubMed ID: 19086016 [TBL] [Abstract][Full Text] [Related]
4. Combined DCE-MRI and single-voxel 2D MRS for differentiation between benign and malignant breast lesions. Lipnick S; Liu X; Sayre J; Bassett LW; Debruhl N; Thomas MA NMR Biomed; 2010 Oct; 23(8):922-30. PubMed ID: 20878970 [TBL] [Abstract][Full Text] [Related]
6. Assessment of early docetaxel response in an experimental model of human breast cancer using DCE-MRI, ex vivo HR MAS, and in vivo 1H MRS. Jensen LR; Huuse EM; Bathen TF; Goa PE; Bofin AM; Pedersen TB; Lundgren S; Gribbestad IS NMR Biomed; 2010 Jan; 23(1):56-65. PubMed ID: 19650073 [TBL] [Abstract][Full Text] [Related]
7. Noninvasive magnetic resonance spectroscopic pharmacodynamic markers of the choline kinase inhibitor MN58b in human carcinoma models. Al-Saffar NM; Troy H; Ramírez de Molina A; Jackson LE; Madhu B; Griffiths JR; Leach MO; Workman P; Lacal JC; Judson IR; Chung YL Cancer Res; 2006 Jan; 66(1):427-34. PubMed ID: 16397258 [TBL] [Abstract][Full Text] [Related]
8. In vivo ³¹P magnetic resonance spectroscopic imaging (MRSI) for metabolic profiling of human breast cancer xenografts. Esmaeili M; Moestue SA; Hamans BC; Veltien A; Kristian A; Engebråten O; Maelandsmo GM; Gribbestad IS; Bathen TF; Heerschap A J Magn Reson Imaging; 2015 Mar; 41(3):601-9. PubMed ID: 24532410 [TBL] [Abstract][Full Text] [Related]
9. Response of choline metabolites to docetaxel therapy is quantified in vivo by localized (31)P MRS of human breast cancer xenografts and in vitro by high-resolution (31)P NMR spectroscopy of cell extracts. Morse DL; Raghunand N; Sadarangani P; Murthi S; Job C; Day S; Howison C; Gillies RJ Magn Reson Med; 2007 Aug; 58(2):270-80. PubMed ID: 17654590 [TBL] [Abstract][Full Text] [Related]
10. Investigation of metabolite changes in the transition from pre-invasive to invasive cervical cancer measured using (1)H and (31)P magic angle spinning MRS of intact tissue. De Silva SS; Payne GS; Thomas V; Carter PG; Ind TE; deSouza NM NMR Biomed; 2009 Feb; 22(2):191-8. PubMed ID: 18833545 [TBL] [Abstract][Full Text] [Related]
11. Quantitative (31)P HR-MAS MR spectroscopy for detection of response to PI3K/mTOR inhibition in breast cancer xenografts. Esmaeili M; Bathen TF; Engebråten O; Mælandsmo GM; Gribbestad IS; Moestue SA Magn Reson Med; 2014 Jun; 71(6):1973-81. PubMed ID: 23878023 [TBL] [Abstract][Full Text] [Related]
12. Comparison of choline and pharmacokinetic parameters in breast cancer measured by MR spectroscopic imaging and dynamic contrast enhanced MRI. Su MY; Baik HM; Yu HJ; Chen JH; Mehta RS; Nalcioglu O Technol Cancer Res Treat; 2006 Aug; 5(4):401-10. PubMed ID: 16866570 [TBL] [Abstract][Full Text] [Related]
13. Assessment of therapeutic response of locally advanced breast cancer (LABC) patients undergoing neoadjuvant chemotherapy (NACT) monitored using sequential magnetic resonance spectroscopic imaging (MRSI). Danishad KK; Sharma U; Sah RG; Seenu V; Parshad R; Jagannathan NR NMR Biomed; 2010 Apr; 23(3):233-41. PubMed ID: 20175134 [TBL] [Abstract][Full Text] [Related]
14. Current dilemmas and future perspectives for breast cancer screening with a focus on optimization of magnetic resonance spectroscopic imaging by advances in signal processing. Belkic K Isr Med Assoc J; 2004 Oct; 6(10):610-8. PubMed ID: 15473589 [TBL] [Abstract][Full Text] [Related]
15. Quantification of metabolites in breast cancer patients with different clinical prognosis using HR MAS MR spectroscopy. Sitter B; Bathen TF; Singstad TE; Fjøsne HE; Lundgren S; Halgunset J; Gribbestad IS NMR Biomed; 2010 May; 23(4):424-31. PubMed ID: 20101607 [TBL] [Abstract][Full Text] [Related]
16. [1H magnetic resonance spectroscopy of the prostate]. Mueller-Lisse UG; Scherr M Radiologe; 2003 Jun; 43(6):481-8. PubMed ID: 12827263 [TBL] [Abstract][Full Text] [Related]
17. Quantitative 31P magnetic resonance spectroscopy of the human breast at 7 T. Wijnen JP; van der Kemp WJ; Luttje MP; Korteweg MA; Luijten PR; Klomp DW Magn Reson Med; 2012 Aug; 68(2):339-48. PubMed ID: 22213214 [TBL] [Abstract][Full Text] [Related]
18. Comparison of HR MAS MR spectroscopic profiles of breast cancer tissue with clinical parameters. Sitter B; Lundgren S; Bathen TF; Halgunset J; Fjosne HE; Gribbestad IS NMR Biomed; 2006 Feb; 19(1):30-40. PubMed ID: 16229059 [TBL] [Abstract][Full Text] [Related]
19. Levels of phospholipid metabolites in breast cancer cells treated with antimitotic drugs: a 31P-magnetic resonance spectroscopy study. Sterin M; Cohen JS; Mardor Y; Berman E; Ringel I Cancer Res; 2001 Oct; 61(20):7536-43. PubMed ID: 11606391 [TBL] [Abstract][Full Text] [Related]
20. 1H magnetic resonance spectroscopy of invasive cervical cancer: an in vivo study with ex vivo corroboration. Mahon MM; Williams AD; Soutter WP; Cox IJ; McIndoe GA; Coutts GA; Dina R; deSouza NM NMR Biomed; 2004 Feb; 17(1):1-9. PubMed ID: 15011245 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]